Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Active not recruiting 4Terminated 3Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1Dermatologic 1

Conditions

Uveal Melanoma 1Neoplasms 1Gastrointestinal Neoplasms 1Advanced Solid Tumor 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Terminated × ulixertinib × Clear all
NCT03417739 2026-02-25

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

Dana-Farber Cancer Institute

Phase 2 Terminated
13 enrolled 9 charts
Dermatologic

Uveal Melanoma

NCT05221320 2025-09-25

Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

BioMed Valley Discoveries, Inc

Phase 2 Terminated
47 enrolled 18 charts
Gastrointestinal

Gastrointestinal Neoplasms, Neoplasms

NCT04488003 2024-06-04

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

BioMed Valley Discoveries, Inc

Phase 2 Terminated
104 enrolled 13 charts
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡